摘要
目的:探讨胸腺瘤最新WHO病理分型与重症肌无力(MG)及临床分期之间的关系.方法:回顾分析1980~2004年间74例因胸腺瘤行胸腺切除的患者,运用最新WHO分型标准(1999)对胸腺瘤进行重新分类,并运用统计软件对新的WHO组织学分型与MG的发生率及Masaoka临床分期之间的关系做进一步分析.结果:①胸腺瘤A型2例,AB型23例,B1型4例,B2型27例,B3型16例,C型2例.其中B2型较AB、B1及B3型易合并MG(P<0.05),A型两例均合并MG,而C型则均未合并MG.②临床Ⅰ期:1例,Ⅱ期:30例,Ⅲ期:38例,Ⅳ期:5例.新的WHO组织学分型与Masaoka分期之间关系密切(P<0.01).结论:新WHO组织学分型与胸腺瘤合并MG的发生率之间有一定关系,同时能反映其临床分期及评价患者的预后.
Purpose:To investigate the relationship of the latest WHO classification of thymic epithelial tumors(TET) to myasthenia gravis( MG) and clinical stages. Methods:The pathological sections of 74 patients with thymoma f rom 1980~2004 using WHO classification(1999) were reviewed,statistical softwar e was used to analyse the relationship of the WHO classification to MG and clini cal stages. Results:①Two cases of type A, 23 cases of type AB, 4 cases of type B 1 ,27 cases of type B 2 , 16 cases of type B 3 and 2 cases o f type C were classified. Type B 2 is more likely to be accompanied by MG( P<0.05), while no MG occurred for type C.②One patient was in stage Ⅰ,30 we re in stageⅡ,38 were in stage Ⅲ, 5 were in stage Ⅳ. The latest histologic cla ssification significantly correlated with Masaoka stages (P<0.01). Conclusions:The latest WHO classification correlated with occur rence of MG and clinical stages , it can also evaluate the prognosis of patients .
出处
《中国癌症杂志》
CAS
CSCD
2005年第1期55-56,60,共3页
China Oncology
关键词
胸腺瘤
重症肌无力
临床分期
thymoma
myasthenia gravis
clinical stages